Ongoing need for biomarkers to predict disease activity in inflammatory bowel disease
World Journal of Gastroenterology · 14.09.2026 · 32 (34)
DOI: 10.3748/wjg.117754 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 14.09.2026. Verfasst von M Jesús Fernández-Aceñero. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a chronic disease that severely affects patients’ quality of life and is associated with an increased risk of colorectal carcinoma. The advent of new therapies has improved the management of patients with IBD; however, there remains a substantial need to identify factors that can predict disease relapse and guide therapy. For decades, the follow-up of patients with IBD has relied on regular endoscopist surveillance depending on clinical symptoms, despite the well-known discrepancy among clinical, endoscopic, and histopathological findings. Although fecal calprotectin has emerged as a useful and reliable marker of disease activity, there remains a considerable need to identify more accurate and prognostic biomarkers. In this editorial, we comment on the article by Chen et al published in the recent issue of the World Journal of Gastroenterology and review recent advances in the diagnosis and management of IBD.
Zitieren
APA
Fernández-Aceñero, M. J. (2026). Ongoing need for biomarkers to predict disease activity in inflammatory bowel disease. World Journal of Gastroenterology, 32(34). https://doi.org/10.3748/wjg.117754
Vancouver
Fernández-Aceñero MJ. Ongoing need for biomarkers to predict disease activity in inflammatory bowel disease. World Journal of Gastroenterology. 2026;32(34). doi:10.3748/wjg.117754
BibTeX
@article{FernndezAceero2026,
author = {Fernández-Aceñero, M Jesús},
title = {Ongoing need for biomarkers to predict disease activity in inflammatory bowel disease},
journal = {World Journal of Gastroenterology},
year = {2026},
volume = {32},
number = {34},
doi = {10.3748/wjg.117754}
}
EUVIMED